← All trials
NCT06733038
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 15, 2024
- Primary completion
- Apr 1, 2028
- Completion date
- Apr 1, 2029
- First posted
- Dec 13, 2024
- Last posted
- Dec 16, 2024
- Enrollment
- 238
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Gruppo Oncologico del Nord-OvestLead sponsor
- RocheCollaborator
- University of PisaOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.